Literature DB >> 9592104

Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

R J Mandel1, K G Rendahl, S K Spratt, R O Snyder, L K Cohen, S E Leff.   

Abstract

To achieve local, continuous L-DOPA delivery in the striatum by gene replacement as a model for a gene therapy for Parkinson's disease, the present studies used high titer purified recombinant adeno-associated virus (rAAV) containing cDNAs encoding human tyrosine hydroxylase (hTH) or human GTP-cyclohydrolase I [GTPCHI, the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis] or both to infect the 6-OHDA denervated rat striatum. Striatal TH and GTPCHI staining was observed 3 weeks after rAAV transduction, with little detectable perturbation of the tissue. Six months after intrastriatal rAAV transduction, TH staining was present but apparently reduced compared with the 3 week survival time. In a separate group of animals, striatal TH staining was demonstrated 1 year after rAAV transduction. Double staining studies using the neuronal marker NeuN indicated that >90% of rAAV-transduced cells expressing hTH were neurons. Microdialysis experiments indicated that only those lesioned animals that received the mixture of MD-TH and MD-GTPCHI vector displayed BH4 independent in vivo L-DOPA production (mean approximately 4-7 ng/ml). Rats that received the hTH rAAV vector alone produced measurable L-DOPA (mean approximately 1-4 ng/ml) only after receiving exogenous BH4. L-Aromatic amino acid decarboxylase blockade, but not 100 mM KCl-induced depolarization, enhanced L-DOPA overflow, and animals in the non-hTH groups (GTPCHI and alkaline phosphatase) yielded minimal L-DOPA. Although elevated L-DOPA was observed in animals that received mixed hTH and hGTPCHI rAAV vectors, there was no reduction of apomorphine-induced rotational behavior 3 weeks after intrastriatal vector injection. These data demonstrate that purified rAAV, a safe and nonpathogenic viral vector, mediates long-term striatal hTH transgene expression in neurons and can be used to successfully deliver L-DOPA to the striatum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592104      PMCID: PMC6792786     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  69 in total

1.  Estimation of nuclear population from microtome sections.

Authors:  M ABERCROMBIE
Journal:  Anat Rec       Date:  1946-02

2.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector.

Authors:  T J McCown; X Xiao; J Li; G R Breese; R J Samulski
Journal:  Brain Res       Date:  1996-03-25       Impact factor: 3.252

3.  Behavioral effects and gene delivery in a rat model of Parkinson's disease.

Authors:  O Isacson
Journal:  Science       Date:  1995-08-11       Impact factor: 47.728

4.  Diminished decarboxylation of L-DOPA in rat striatum after intrastriatal injections of kainic acid.

Authors:  E Melamed; F Hefti; R J Wurtman
Journal:  Neuropharmacology       Date:  1980-04       Impact factor: 5.250

5.  Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease.

Authors:  P Horellou; E Vigne; M N Castel; P Barnéoud; P Colin; M Perricaudet; P Delaère; J Mallet
Journal:  Neuroreport       Date:  1994-12-30       Impact factor: 1.837

6.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.

Authors:  J H Kordower; T B Freeman; B J Snow; F J Vingerhoets; E J Mufson; P R Sanberg; R A Hauser; D A Smith; G M Nauert; D P Perl
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

7.  Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries.

Authors:  E Melamed; F Hefti; R J Wurtman
Journal:  Brain Res       Date:  1980-09-29       Impact factor: 3.252

8.  Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.

Authors:  L A Schuh; J P Bennett
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

Review 9.  Rationale for continuous dopaminomimetic therapy of Parkinson's disease.

Authors:  T N Chase; F Baronti; G Fabbrini; I J Heuser; J L Juncos; M M Mouradian
Journal:  Neurology       Date:  1989-11       Impact factor: 9.910

10.  NeuN, a neuronal specific nuclear protein in vertebrates.

Authors:  R J Mullen; C R Buck; A M Smith
Journal:  Development       Date:  1992-09       Impact factor: 6.868

View more
  42 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector.

Authors:  M A Passini; J H Wolfe
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

4.  Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.

Authors:  Mei Sun; Guo-Rong Zhang; Lingxin Kong; Courtney Holmes; Xiaodan Wang; Wei Zhang; David S Goldstein; Alfred I Geller
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

5.  Gene transfer to the cerebellum.

Authors:  Jean-Pierre Louboutin; Beverly A S Reyes; Elisabeth J Van Bockstaele; David S Strayer
Journal:  Cerebellum       Date:  2010-12       Impact factor: 3.847

6.  Efficient CNS gene delivery by intravenous injection.

Authors:  Jean-Pierre Louboutin; Alena A Chekmasova; Elena Marusich; J Roy Chowdhury; David S Strayer
Journal:  Nat Methods       Date:  2010-10-17       Impact factor: 28.547

7.  The vesicular glutamate transporter-1 upstream promoter and first intron each support glutamatergic-specific expression in rat postrhinal cortex.

Authors:  Guo-rong Zhang; Xu Li; Haiyan Cao; Hua Zhao; Alfred I Geller
Journal:  Brain Res       Date:  2010-12-21       Impact factor: 3.252

Review 8.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

9.  Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.

Authors:  J-P Louboutin; L Agrawal; B A S Reyes; E J van Bockstaele; D S Strayer
Journal:  Neuroscience       Date:  2012-04-21       Impact factor: 3.590

Review 10.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.